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Introduction
This joint position paper, composed by an author group of
members of the Cardiovascular and Interventional Radio-
logical Society of Europe (CIRSE) and the European
Society of Hypertension (ESH), is being published jointly
in the Cardiovascular and Interventional Radiology Journal
and the Journal of Hypertension. The paper attempts to
review the evidence and provide some guidance and for-
ward direction for this new and potentially still valuable
technique. The article presented here is a brief executive
summary of the full paper which can be found on the
CIRSE and ESH websites.
Methodology
CIRSE and the ESH produced this joint position paper
using the following process. The formal decision of the two
societies to draft a multidisciplinary joint position paper
was taken in November 2013, following the discussion on
the potential benefits of a joint statement on the occasion of
the CIRSE annual meeting 2013 in Barcelona.
Both societies identified and nominated recognised
experts as members of the joint writing group for the
document. In the case of CIRSE, the renal denervation task
force, an already established group of senior interventional
radiologists and CIRSE members with significant experi-
ence in performing renal artery denervation, represented
the society in the working group. In the case of ESH, the
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eminent members of the joint writing group were selected
by the society’s council, based on their expertise.
In early 2014, the first writing workshop was held and a
timeline for the drafting process was agreed upon. In the
period following the workshop, it was announced that the
results of the pivotal HTN-3 regulatory trial would soon be
published. Therefore, a new timeline was devised to be
able to take into account these important results.
Once HTN-3 had been published, a critical review of the
currently available position statements, peer-reviewed
articles and regulatory documents in the field of renal
denervation was performed with regard to methodology,
results and conclusions. Several further drafting workshops
and teleconferences were held between the two groups to
discuss interpretations and plan the writing phase.
The drafting process of this joint position paper allowed
for an extensive exchange among interventional radiolo-
gists and hypertension specialists, and achieved a consen-
sus document agreeable to all the contributors. However,
the negative results of the first randomised controlled trial
with sham control of this therapy that were published
during the drafting process had a significant impact on the
ongoing assessment. The publication of this position paper
intervenes at a point in time where renal artery denervation
seems to have lost its momentum in Europe, but the joint
writing group deems it thus all the more important to give a
comprehensive account of this therapy, including the
potential benefits and urgent need for more scientific data
of randomised trials.
Review of Content
Renal denervation (RDN) was reported as an exciting new
development for the treatment of resistant hypertension in
2009 [1]. This minimally invasive technique gained rapid
acceptance across the globe, although the majority of
procedures were carried out in one country (Germany). The
Symplicity HTN-2 randomised trial [2] added further
supportive evidence (both efficacy and safety) and by late
2013 no fewer than 60 companies were investing in the
technology. The global potential is obvious with 5–10 % of
hypertensive patients (a third of the world population)
falling into the ‘‘resistant’’ category. They are a very high-
risk group, and RDN has the potential to result in a marked
reduction in cardiovascular morbidity and mortality.
The Symplicity HTN-3 FDA regulatory randomised
trial, which would prove pivotal in the assessment of the
therapy, included a sham arm and used ABPM in the lar-
gest trial to date (n = 535). Therefore, it addressed many
of the shortcomings of the earlier trials. The results pub-
lished in NEJM in March 2014 showed a failure to achieve
the primary efficacy outcome in reducing office blood
pressure at 6 months compared to the sham procedure. The
safety endpoint was met with a major adverse event rate of
1.4 % [3].
It is difficult to exaggerate the fallout from this trial and
its effect across the globe was almost immediate and per-
haps also exaggerated. There has been much criticism and
praise of HTN-3 and a wide range of opinions persist.
Although RDN appears to be consistently safe across all
trials (albeit with limited short-term follow-up), the main
controversy is with regard to efficacy and here the trials
have produced mixed and conflicting results. As a result of
HTN-3 in particular, there has been a dramatic reduction in
the use of RDN in all countries in the order of 80 %, and
two major companies have withdrawn from the market.
The trial was well designed but has been criticised in
several respects. One hundred and eleven different inter-
ventionists treated the 364 patients in the active arm (34 %
of operators only carried out a single procedure). The
majority of patients (N = 253) did not have a successful
four-quadrant ablation [4]. It must, however, be noted that
the guidance technologies applicable to RDN (for example
ultrasound) continue to evolve and may offer a more
effective denervation in the future.
The interpretation of results also proved challenging.
The anatomical studies of human renal nerve anatomy are
limited and inconsistent, and further research is needed to
guide RDN devices for the future [5, 6]. RDN is currently
severely hampered by having no easy method to measure
the completeness of denervation, which largely remains a
‘‘blind technique’’. Variations in the use of aldosterone
antagonists drug turbulence in HTN-3 may have introduced
confounders.
There are lessons to be learned from previous RDN trial
designs and this group remains interested in RDN, although
high-quality research is needed before widespread adoption
of this expensive technology. This research should include
sham arms, use of ABPM to select and monitor patients,
objective assessment of drug adherence and long-term
assessment of the renal artery and renal function. These
trials should be conducted in high-volume specialist cen-
tres with the appropriate physician expertise in hyperten-
sion management supported by well-trained and audited
interventionists. Participation in clinical trials and reg-
istries is strongly recommended.
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